Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 221

1.

Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice.

Bornstein S, Moschetta M, Kawano Y, Sacco A, Huynh D, Brooks D, Manier S, Fairfield H, Falank C, Roccaro AM, Nagano K, Baron R, Bouxein M, Vary C, Ghobrial IM, Rosen CJ, Reagan MR.

Endocrinology. 2017 Oct 1;158(10):3369-3385. doi: 10.1210/en.2017-00299.

PMID:
28977604
2.

Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, Giustini V, Bertoli D, Sottini A, Valotti M, Ghidini C, Serana F, Malagola M, Imberti L, Russo D, Montanelli A, Rossi G, Reagan MR, Maiso P, Paiva B, Ghobrial IM, Roccaro AM.

Curr Osteoporos Rep. 2017 Oct;15(5):499-506. doi: 10.1007/s11914-017-0399-3. Review.

PMID:
28889371
3.

Established and Novel Prognostic Biomarkers in Multiple Myeloma.

Bustoros M, Mouhieddine TH, Detappe A, Ghobrial IM.

Am Soc Clin Oncol Educ Book. 2017;37:548-560. doi: 10.14694/EDBK_175175. Review.

4.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.

5.

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, Ebright RY, Shi J, Park J, Glavey SV, Devine WG, Liu CJ, Leleu X, Quesnel B, Roche-Lestienne C, Snyder JK, Brown LE, Gray N, Bradner J, Whitesell L, Porco JA Jr, Ghobrial IM.

Sci Transl Med. 2017 May 10;9(389). pii: eaal2668. doi: 10.1126/scitranslmed.aal2668.

PMID:
28490664
6.

Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.

Gustine JN, Meid K, Dubeau T, Hunter ZR, Xu L, Yang G, Ghobrial IM, Treon SP, Castillo JJ.

Br J Haematol. 2017 Jun;177(5):717-725. doi: 10.1111/bjh.14743. Epub 2017 May 9.

PMID:
28485115
7.

A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation.

Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan M, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, Roccaro AM.

Am J Hematol. 2017 Aug;92(8):E138-E145. doi: 10.1002/ajh.24778. Epub 2017 Jun 15.

PMID:
28474779
8.

The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.

Sacco A, Fenotti A, Affò L, Bazzana S, Russo D, Presta M, Malagola M, Anastasia A, Motta M, Patterson CJ, Rossi G, Imberti L, Treon SP, Ghobrial IM, Roccaro AM.

Oncotarget. 2017 May 23;8(21):35435-35444. doi: 10.18632/oncotarget.16130. Review.

9.

IgM myeloma: A multicenter retrospective study of 134 patients.

Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA.

Am J Hematol. 2017 Aug;92(8):746-751. doi: 10.1002/ajh.24753. Epub 2017 May 26.

PMID:
28383205
10.

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM.

Cell Rep. 2017 Apr 4;19(1):218-224. doi: 10.1016/j.celrep.2017.03.025.

11.

Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.

Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, Roccaro AM, Hynes RO, Ghobrial IM.

Leukemia. 2017 Nov;31(11):2426-2434. doi: 10.1038/leu.2017.102. Epub 2017 Mar 27.

PMID:
28344315
12.

Prognostic role of circulating exosomal miRNAs in multiple myeloma.

Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, Roccaro AM, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM.

Blood. 2017 Apr 27;129(17):2429-2436. doi: 10.1182/blood-2016-09-742296. Epub 2017 Feb 17.

PMID:
28213378
13.

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma.

Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE.

Am J Hematol. 2017 May;92(5):448-453. doi: 10.1002/ajh.24671. Epub 2017 Mar 10.

PMID:
28211162
14.

Multiple Myeloma and the Immune Microenvironment.

Kawano Y, Roccaro AM, Ghobrial IM, Azzi J.

Curr Cancer Drug Targets. 2017;17(9):806-818. doi: 10.2174/1568009617666170214102301.

PMID:
28201978
15.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D.

Br J Haematol. 2017 Mar;176(6):929-938. doi: 10.1111/bjh.14493. Epub 2017 Jan 20.

PMID:
28107546
16.

Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.

Batth IS, Mitra A, Manier S, Ghobrial IM, Menter D, Kopetz S, Li S.

Ann Oncol. 2017 Mar 1;28(3):468-477. doi: 10.1093/annonc/mdw619.

PMID:
27998963
17.

Exosomes in Tumor Angiogenesis.

Salem KZ, Moschetta M, Sacco A, Imberti L, Rossi G, Ghobrial IM, Manier S, Roccaro AM.

Methods Mol Biol. 2016;1464:25-34.

PMID:
27858353
18.

Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).

Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM.

Clin Cancer Res. 2017 May 15;23(10):2400-2404. doi: 10.1158/1078-0432.CCR-16-1918. Epub 2016 Nov 11.

PMID:
27836860
19.

Epigenomics in Waldenstrom's macroglobulinaemia.

Sacco A, Fenotti A, Bazzana S, Imberti L, Rossi G, Patterson CJ, Treon SP, Ghobrial IM, Roccaro AM.

Best Pract Res Clin Haematol. 2016 Jun;29(2):156-160. doi: 10.1016/j.beha.2016.08.022. Epub 2016 Sep 25. Review.

PMID:
27825461
20.

Genomic complexity of multiple myeloma and its clinical implications.

Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM.

Nat Rev Clin Oncol. 2017 Feb;14(2):100-113. doi: 10.1038/nrclinonc.2016.122. Epub 2016 Aug 17. Review.

PMID:
27531699

Supplemental Content

Loading ...
Support Center